Enfortumab Vedotin-ejfv (Solution) (CAS: 1346452-25-2)
Enfortumab vedotin-ejfv is an antibody-drug conjugate (ADC) targeting Nectin-4, a protein overexpressed in various cancers. It combines an anti-Nectin-4 antibody with monomethyl auristatin E (MMAE), a microtubule-disrupting cytotoxic agent.
Key Features:
- Targeted Therapy: Binds specifically to Nectin-4 on cancer cells, delivering MMAE directly to the tumor.
- Cytotoxic Payload: MMAE disrupts microtubule function, causing cancer cell death.
- Enhanced Efficacy: Targets the tumor site, minimizing systemic toxicity.
Applications:
- Metastatic Urothelial Cancer: Approved for patients previously treated with a PD-(L)1 inhibitor and platinum chemotherapy.
- Combination Therapy: Studied in combination with pembrolizumab for untreated advanced urothelial cancer.
Handling and Storage:
- Storage: Store at -20°C, protected from light and moisture.
- Handling: Use standard laboratory precautions.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.